Influenza viruses: Update on epidemiology, clinical features, treatment and vaccination

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 3, 2014, Pages 242-246

  Kidd, Mike ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

adjuvant; antiviral; H1N1pdm2009; H5N1; H7N9; influenza

Indexed keywords

FAVIPIRAVIR; INFLUENZA VACCINE; LANINAMIVIR; OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; VIRUS DNA; VIRUS VACCINE;

CLINICAL FEATURE; DISEASE SEVERITY; GENE SEQUENCE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; REVIEW; VIRUS GENOME; ANIMAL; ANTIVIRAL RESISTANCE; DNA SEQUENCE; FEMALE; GENETICS; INFLUENZA IN BIRDS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N9; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MALE; PANDEMIC; PATHOGENICITY; POULTRY; SEASON; SENTINEL SURVEILLANCE; TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MALE; PANDEMICS; POULTRY; SEASONS; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; VIRAL VACCINES; ZANAMIVIR;

EID: 84897579149     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000049     Document Type: Review

References (38)

1. Zambon M. Influenza and other emerging respiratory viruses. Medicine 2014; 42:45-51.
2. Chen R, Holmes EC. Avian influenza virus exhibits rapid evolutionary dynamics. Mol Biol Evol 2006; 23:2336-2341.
3. Avian influenza (56): Vietnam,H5N1, spread: International Society for Infectious Diseases; 2014 [Accessed on 04 January 2014]. http://www.promedmail. org/.
4. World Health Organisation. Number of confirmed human cases of avian influenza A (H7N9) reported to WHO 2013 [Accessed on 20 January2014]. http://www.who.int/influenza/human-animal-interface/influenza-h7n9/Data- Reports/en/index.html.
5. Ip DK, Liao Q, Wu P, et al. Detection of mild to moderate influenza A/H7N9 infection by China's national sentinel surveillance system for influenza-like illness: case series. BMJ 2013; 346:f3693.
6. Cowling BJ, Freeman G, Wong JY, et al. Preliminary inferences on the agespecific seriousness of human disease caused by avian influenza A(H7N9) infections in China, March to April 2013. Euro Surveill 2013; 18:20475.
7. Skowronski DM, Janjua NZ, Kwindt TL, De Serres G. Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013. Euro Surveill 2013; 18:20465.
8. Yu H, Wu JT, Cowling BJ, et al. Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. Lancet 2014; 383:541-548.
9. Chen E, Chen Y, Fu L, et al. Human infection with avian influenza A(H7N9) virus re-emerges in China in winter 2013. Euro Surveill 2013; 18:20616.
10. Jonges M, Meijer A, Fouchier RA, et al. Guiding outbreak management by the use of influenza A(H7Nx) virus sequence analysis. Euro Surveill 2013; 18:20460.
11. Fonseca K, Lavoie M, Talbot J, et al. Avian influenza, Human (13): Canada ex China (Beijing), H5N1, Fatal, Case Report 2014 [updated 12 January 2014; Accessed on 20 January 2014]. http://www.promedmail.org/direct.php? id=20140112.2167282.
12. Avian Influenza, Human (36): China (Jiangxi) H10N8 2014 [Accessed on 26 January 2014]. http://www.promedmail.org/.
13. Jhung MA, Epperson S, Biggerstaff M, et al. Outbreak of variant influenza A(H3N2) virus in the United States. Clin Infect Dis 2013; 57:1703-1712. Detailed analysis of the H3N2v outbreak in humans.
14. Wong KK, Gambhir M, Finelli L, et al. Transmissibility of variant influenza from swine to humans: a modeling approach. Clin Infect Dis 2013; 57 (Suppl 1): S16-S22.
15. Pearce MB, Jayaraman A, Pappas C, et al. Pathogenesis and transmission of swine origin A(H3N2)v influenza viruses in ferrets. Proc Natl Acad Sci U SA 2012; 109:3944-3949.
16. Simonsen L, Spreeuwenberg P, Lustig R, et al. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med 2013; 10:e1001558.
17. Renzette N, Caffrey DR, Zeldovich KB, et al. Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro. J Virol 2014; 88:272-281.
18. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin Infect Dis 2013; 57:1511-1519.
19. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346:f3039.
20. Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374:1036.
21. Chan-Tack KM, GaoF A. Himaya AC, et al. Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States. J Infect Dis 2013; 207:196-198.
22. Lee CM, Weight AK, Haldar J, et al. Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection. Proc Natl Acad Sci U SA 2012; 109:20385-20390.
23. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575-2582.
24. Efficacy and Safety Study of Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Adults With Influenza (Igloo). ClinicalTrials.gov: National Institues for Health, USA; 2013 [Accessed on 20 January 2014]. http://clinicaltrials.gov/ ct2/show/record/NCT01793883.
25. De Clercq E. Dancing with chemical formulae of antivirals: a panoramic view (Part 2). Biochem Pharmacol 2013; 86:1397-1410.
26. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-454.
27. Tarbet EB, Vollmer AH, Hurst BL, et al. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Arch Virol 2013. [Epub ahead of print]
28. Chiu C, Wrammert J, Li GM, et al. Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann N Y Acad Sci 2013; 1283:13-21.
29. Kumar P, Khanna M, Kumar B, et al. A conserved matrix epitope based DNA vaccine protects mice against influenza A virus challenge. Antiviral Res 2012; 93:78-85.
30. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013; 64:189-202.
31. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PloS One 2012; 7:e33723.
32. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013; 136 (Pt 8):2486-2496.
33. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.
34. ECDC. Narcolepsy in association with pandemic influenza vaccination (a multicountry European epidemiological investigation). ECDC; 2012.
35. De la Herran-Arita AK, Kornum BR, Mahlios J, et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 2013; 5:216ra176.
36. Dyer C. UK government is to reconsider claims of children who developed narcolepsy after vaccination. BMJ 2013; 347:f5645.
37. Tsai TF, Crucitti A, Nacci P, et al. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; 43:702-706.
38. Crucitti A, Tsai TF. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update. Scand J Infect Dis 2011; 43:993.